X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (34) 34
humans (32) 32
oncology (31) 31
middle aged (25) 25
aged (22) 22
female (22) 22
male (22) 22
adult (18) 18
cancer (18) 18
neoplasms - drug therapy (15) 15
treatment outcome (14) 14
care and treatment (12) 12
antineoplastic agents - therapeutic use (11) 11
clinical trials (11) 11
pharmacology & pharmacy (10) 10
aged, 80 and over (9) 9
chemotherapy (9) 9
solid tumors (9) 9
tumors (9) 9
antineoplastic agents - adverse effects (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
medical research (7) 7
medicine & public health (7) 7
neoplasm staging (7) 7
poly polymerase (7) 7
administration, oral (6) 6
analysis (6) 6
mutation (6) 6
ovarian cancer (6) 6
pharmacology/toxicology (6) 6
prognosis (6) 6
research (6) 6
young adult (6) 6
antineoplastic agents - pharmacokinetics (5) 5
antineoplastic agents - pharmacology (5) 5
article (5) 5
breast cancer (5) 5
cancer research (5) 5
clinical trials, phase i as topic (5) 5
drug development (5) 5
expression (5) 5
hematology, oncology and palliative medicine (5) 5
neoplasm metastasis (5) 5
neoplasms - metabolism (5) 5
neoplasms - pathology (5) 5
olaparib (5) 5
ovarian-cancer (5) 5
adolescent (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
drug administration schedule (4) 4
inhibition (4) 4
inhibitor (4) 4
metastasis (4) 4
parp inhibitor (4) 4
patients (4) 4
pharmacokinetics (4) 4
piperazines - therapeutic use (4) 4
resistance (4) 4
retrospective studies (4) 4
advanced solid tumors (3) 3
androgen antagonists - therapeutic use (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antineoplastic agents (3) 3
antineoplastic agents - administration & dosage (3) 3
apoptosis (3) 3
biomarkers (3) 3
breast-cancer (3) 3
breast-cancer cells (3) 3
clinical-trials (3) 3
combination (3) 3
complications and side effects (3) 3
disease progression (3) 3
dose-response relationship, drug (3) 3
drug resistance (3) 3
drugs (3) 3
end-points (3) 3
health aspects (3) 3
histone deacetylase inhibitor (3) 3
immunoglobulins, intravenous (3) 3
internal medicine (3) 3
maintenance therapy (3) 3
maximum tolerated dose (3) 3
medicine, experimental (3) 3
molecular targeted therapy (3) 3
mutations (3) 3
neoplasms - blood (3) 3
neoplasms - diagnosis (3) 3
neoplasms - physiopathology (3) 3
oncology, experimental (3) 3
ovarian neoplasms - drug therapy (3) 3
ovarian neoplasms - genetics (3) 3
ovarian neoplasms - pathology (3) 3
patient outcomes (3) 3
phase-i (3) 3
phthalazines - therapeutic use (3) 3
poly polymerase inhibitors (3) 3
prostate cancer (3) 3
prostate-specific antigen - blood (3) 3
protein kinase inhibitors - therapeutic use (3) 3
quinazolines - administration & dosage (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacokinetics, ISSN 0312-5963, 9/2019, Volume 58, Issue 9, pp. 1165 - 1174
Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially renally cleared. We investigated the pharmacokinetics and safety of olaparib in... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | INHIBITOR | PHARMACOLOGY & PHARMACY | CANCER | Index Medicus
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e14054 - e14054
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. e17671 - e17671
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3742 - 3748
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. 2024 - 2024
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. 2025 - 2025
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 12/2011, Volume 20, Issue 12, pp. 1723 - 1732
Introduction: Histone deacetylase (HDAC) inhibitors have recently emerged as a novel and active class of anticancer agents. Belinostat is one member of the... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.